Seeking Alpha
17 Dec 2025, 19:44 UTC · 47w ago
Verdict
Headline leans bullish. We score IMNM +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
More positive than 99% of ticker scores this week
Search tags
What the story claims
3 claims · scored −1 bearish … +1 bullish
Immunome's phase 3 RINGSIDE trial for varegacestat showed an 84% risk reduction in progression or death and a 56% objective response rate.
So whatStatistically significant Phase 3 success with record-breaking response rates is a primary catalyst for biotech valuation increases.
More positive than 99% of claims this week
Immunome plans to file a New Drug Application (NDA) for varegacestat in Q2 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 85% of claims this week
Phase 1 data for IM-1021 in lymphoma is expected in 2026.
So whatAdds future pipeline optionality, though early-phase data is less market-moving than Phase 3 results.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reported statistically significant positive phase 3 results and has a 'Strong Buy' rating.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
13m ago
−21.8%
Price is moving against the score
$18.37 vs $23.48 close before publication (Dec 16) · not market-adjusted
IMNM chart →
